This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arbeit, J. M. Articles by Pinkel, D. Search for Related Content PubMed PubMed Citation Articles by Arbeit, J. M. Articles by Pinkel, D.

Difluoromethylornithine Chemoprevention of Epidermal Carcinogenesis in K14-HPV16 Transgenic Mice¹

UCSF Cancer Center, San Francisco, California 94143 [J. M. A., R. R. R., B. H., D. P.]; Division of Cancer Chemoprevention, National Cancer Institute, Bethesda, Maryland 20262 [G. K., R. L.]; Grace Cancer Drug Center, Roswell Park Memorial Cancer Center, Buffalo, New York 14263 [C. P.]; Veterinary and Tumor Pathology Section, Office of Laboratory and Animal Science, National Cancer Institute, Frederick, Maryland 21702 [J. M. W.]; and Department of Surgery, UCSF/Mt Zion Medical Center, San Francisco, California 94143-1674 [J. M. A.]

To be informative for chemoprevention, animal models must both closely emulate human disease and possess surrogate endpoint biomarkers that facilitate rapid drug screening. This study elucidated site-specific histopathological and biochemical surrogate endpoint biomarkers of spontaneous epidermal carcinogenesis in K14-HPV16 transgenic mice and demonstrated that the incidence and severity of these markers were decreased by the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO). The cumulative incidence of visible epidermal cancers in 127 untreated transgenic mice was 42% by 52 weeks of age, most frequently affecting the chest as flat lesions in association with chronic ulcers, or in the ear as protuberant masses. Microscopic malignancies were detected in 39% of 32-week-old transgenic mice and were found to emerge from precursor lesions that were of two distinct types: dysplastic sessile ear papillomas and hyperproliferative follicular/interfollicular chest dysplasias. ODC activity and tissue polyamine contents were differentially elevated in ear and chest skin during carcinogenesis, such that there was a marked elevation of both parameters of polyamine metabolism as early as 4 weeks of age in the ear, whereas in the chest, polyamine metabolism was increased significantly only in the late stages of neoplastic progression and in epidermal cancers. Administration of 1.0% DFMO in the drinking water from 4 to 32 weeks of age prevented both visible and microscopic malignancies and significantly decreased the incidence of chest and ear precursor lesions. ODC activity and tissue putrescine content were markedly diminished by DFMO chemoprevention in ear skin, whereas there was a more modest decline of these parameters in chest skin. DFMO treatment of transgenic mice from 28 to 32 weeks of age was associated with an absence of ear cancer and a marked regression of dysplastic papillomas. In contrast, the results in chest skin were complex in that the severity of chest precursors diminished, but their incidence was unchanged, and microscopic cancers were still detectable within these lesions. Collectively, this study highlights the utility of multistage epidermal carcinogenesis in K14-HPV16 transgenic mice both for the study of the biology of, and as a screening tool for, novel drugs and chemopreventive regimens.

This article has been cited by other articles:

				D. J. Feith, S. Origanti, P. L. Shoop, S. Sass-Kuhn, and L. M. Shantz Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis Carcinogenesis, May 1, 2006; 27(5): 1090 - 1098. [Abstract] [Full Text] [PDF]

				D. J. Feith, D. K. Bol, J. M. Carboni, M. J. Lynch, S. Sass-Kuhn, P. L. Shoop, and L. M. Shantz Induction of Ornithine Decarboxylase Activity Is a Necessary Step for Mitogen-Activated Protein Kinase Kinase-Induced Skin Tumorigenesis Cancer Res., January 15, 2005; 65(2): 572 - 578. [Abstract] [Full Text] [PDF]

				R. R. Riley, S. Duensing, T. Brake, K. Munger, P. F. Lambert, and J. M. Arbeit Dissection of Human Papillomavirus E6 and E7 Function in Transgenic Mouse Models of Cervical Carcinogenesis Cancer Res., August 15, 2003; 63(16): 4862 - 4871. [Abstract] [Full Text] [PDF]

				H. Rebel, H. van Steeg, R. B. Beems, R. Schouten, F. R. de Gruijl, and C. Terleth Suppression of UV Carcinogenesis by Difluoromethylornithine in Nucleotide Excision Repair-deficient Xpa Knockout Mice Cancer Res., March 1, 2002; 62(5): 1338 - 1342. [Abstract] [Full Text] [PDF]

				J. E. Green, M.-A. Shibata, E. Shibata, R. C. Moon, M. R. Anver, G. Kelloff, and R. Lubet 2-Difluoromethylornithine and Dehydroepiandrosterone Inhibit Mammary Tumor Progression but not Mammary or Prostate Tumor Initiation in C3(1)/SV40 T/t-antigen Transgenic Mice Cancer Res., October 1, 2001; 61(20): 7449 - 7455. [Abstract] [Full Text] [PDF]

				S. M. Fischer, M. Lee, and R. A. Lubet Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice Carcinogenesis, January 1, 2001; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]

				D. A. Elson, H. E. Ryan, J. W. Snow, R. Johnson, and J. M. Arbeit Coordinate Up-Regulation of Hypoxia Inducible Factor (HIF)-1{{alpha}} and HIF-1 Target Genes during Multi-Stage Epidermal Carcinogenesis and Wound Healing Cancer Res., November 1, 2000; 60(21): 6189 - 6195. [Abstract] [Full Text]

				P. P. Carbone, J. A. Douglas, J. Thomas, K. Tutsch, M. Pomplun, M. Hamielec, and D. Pauk Bioavailability Study of Oral Liquid and Tablet Forms of {{alpha}}-Difluoromethylornithine Clin. Cancer Res., October 1, 2000; 6(10): 3850 - 3854. [Abstract] [Full Text]

				S. Gupta, N. Ahmad, S. R. Marengo, G. T. MacLennan, N. M. Greenberg, and H. Mukhtar Chemoprevention of Prostate Carcinogenesis by {{alpha}}-Difluoromethylornithine in TRAMP Mice Cancer Res., September 1, 2000; 60(18): 5125 - 5133. [Abstract] [Full Text]

				R. F. Jacoby, C. E. Cole, K. Tutsch, M. A. Newton, G. Kelloff, E. T. Hawk, and R. A. Lubet Chemopreventive Efficacy of Combined Piroxicam and Difluoromethylornithine Treatment of Apc Mutant Min Mouse Adenomas, and Selective Toxicity against Apc Mutant Embryos Cancer Res., April 1, 2000; 60(7): 1864 - 1870. [Abstract] [Full Text]

				D. A. Elson, R. R. Riley, A. Lacey, G. Thordarson, F. J. Talamantes, and J. M. Arbeit Sensitivity of the Cervical Transformation Zone to Estrogen-induced Squamous Carcinogenesis Cancer Res., March 1, 2000; 60(5): 1267 - 1275. [Abstract] [Full Text]